Evidence implicating Eph receptor tyrosine kinases and their ephrin ligands (that together
make up the 'Eph system') in cancer development and progression has been accumulating …

Over the past decade, rapid advances in genomics, proteomics and functional genomics
technologies that enable in-depth interrogation of cancer genomes and proteomes and high …

Malignant transformation can result in melanoma cells that resemble different stages of their
embryonic development. Our gene expression analysis of human melanoma cell lines and …

Clinically acquired resistance to MAPK inhibitor (MAPKi) therapies for melanoma cannot be
fully explained by genomic mechanisms and may be accompanied by co-evolution of intra …

Mechanical cues from the extracellular matrix (ECM) regulate various cellular processes via
distinct mechanotransduction pathways. In breast cancer, increased ECM stiffness promotes …

More than 25 years of research and preclinical validation have defined EphA2 receptor
tyrosine kinase as a promising molecular target for clinical translation in cancer treatment …

Congenital cataracts, the most common cause of visual impairment and blindness in
children worldwide, have diverse etiologies. According to statistics analysis, about one …

Crosstalk between inflammatory signalling pathways and receptor tyrosine kinases has
been revealed as an indicator of cancer malignant progression. In the present study, we …

Background Melanoma is a heterogeneous tumour, but the impact of this heterogeneity
upon therapeutic response is not well understood. Methods Single cell mRNA analysis was …

Purpose: The clinical use of MEK inhibitors in uveal melanoma is limited by the rapid
acquisition of resistance. This study has used multiomics approaches and drug screens to …